Nystatin/Neomycin Sulfate/Thiostrepton/Triamcinolone Acetonide Ointment

Verify with FDA CVM →

13 adverse event reports submitted to the FDA

Important: Adverse event reports do not establish that a drug caused or contributed to the event. Consult your veterinarian before making treatment decisions.
13
Total Reports
0
Deaths Reported
0.0%
Death Rate

Active Ingredients

Nystatin/Neomycin Sulfate/Thiostrepton/Triamcinolone Acetonide Ointment

Administration Routes

TopicalUnknownAuricular (Otic)

Species Affected

Dog 7
Cat 6

Most Affected Breeds

Domestic Shorthair 3
Domestic Longhair 1
Retriever - Labrador 1
Catahoula Leopard Dog 1
Siamese 1
Maltese 1
Pug 1
Domestic Mediumhair 1
Pointer (unspecified) 1
Retriever - Golden 1

Most Reported Reactions

Application site alopecia 5
Application site scab 4
Application site erythema 4
Application site ulcer 4
Application site pruritus 3
Agitation 2
Anorexia 2
Pruritus 2
Behavioural disorder NOS 2
Pain NOS 2
Ear discharge 2
Other abnormal test result NOS 2

Outcome Breakdown

Recovered/Normal
6 (46.2%)
Outcome Unknown
5 (38.5%)
Recovered with Sequela
1 (7.7%)
Ongoing
1 (7.7%)

Data Summary

Metric Value
Total adverse event reports 13
Reports involving death 0
Case-fatality rate (reported events) 0.0%
Distinct species in reports 2
Distinct breeds in reports 11
Distinct reactions reported 20
Active ingredients on file 1

Source: FDA Center for Veterinary Medicine — Adverse Event Reporting (CVM AER). Counts reflect voluntary reports only.

Nystatin/Neomycin Sulfate/Thiostrepton/Triamcinolone Acetonide Ointment Adverse Event Insights

The FDA Center for Veterinary Medicine database currently holds 13 adverse event reports referencing Nystatin/Neomycin Sulfate/Thiostrepton/Triamcinolone Acetonide Ointment, including 0 reports in which the animal died — a 0.0% case-fatality figure among reported events only, not a population-level mortality rate. Active ingredient on file: Nystatin/Neomycin Sulfate/Thiostrepton/Triamcinolone Acetonide Ointment. Reported administration routes include Topical, Unknown, Auricular (Otic). These numbers reflect voluntary submissions from pet owners, veterinarians, and manufacturers and therefore under-represent mild events and over-represent severe ones — a pattern the FDA has documented repeatedly for pharmacovigilance datasets.

The species most frequently named in Nystatin/Neomycin Sulfate/Thiostrepton/Triamcinolone Acetonide Ointment reports are Dog (7 reports), Cat (6 reports), with Dog accounting for the largest share. Within those species, Domestic Shorthair (3), Domestic Longhair (1), Retriever - Labrador (1) appear most often — though breed popularity and ownership density shape these counts as much as any drug-specific sensitivity. This distribution matters because the same active ingredient can behave very differently across body sizes, ages, and species physiology.

The most commonly reported clinical signs associated with Nystatin/Neomycin Sulfate/Thiostrepton/Triamcinolone Acetonide Ointment are Application site alopecia (5), Application site scab (4), Application site erythema (4), Application site ulcer (4). Of the 13 reports with a coded outcome, Recovered/Normal is the leading category at 46.2%. Because FDA adverse event data describes correlation rather than causation, these figures are best used to frame informed questions with a veterinarian and to compare reporting patterns across related products — not as a standalone safety verdict on Nystatin/Neomycin Sulfate/Thiostrepton/Triamcinolone Acetonide Ointment.

Source: FDA Center for Veterinary Medicine — Adverse Event Reports FDA Center for Veterinary Medicine — Adverse Event Reports Data reflects voluntary submissions and may not represent actual incidence rates

Related

Data sourced from official AKC, AVMA, ACVO, and breed-club veterinary references. See our methodology for details. Retrieved and formatted by PlainBreed Editorial